Table 1 Potency and efficacy of SA10SC-RLX in head-to-head comparison with relaxin in different cell types with endogenous or recombinant expression of human or rat RXFP1. Relative EC50s (EC50rel) and Emax were determined with SAS procedure via Biost@t-SPEED-LTS v2.4 internal software using the 4-parameter logistic model. The geometric means of the EC50rel values were calculated with confidence intervals (CI) at 95% level. For Emax comparison between relaxin and SA10SC-RLX, normality hypothesis was confirmed for each group and a paired T test was performed. In the absence of normality hypothesis, a Wilcoxon test was performed. For the EC50 comparison, the same method was applied after log transformation of the value (*P < 0.05 vs relaxin).

From: Characterization of a new potent and long-lasting single chain peptide agonist of RXFP1 in cells and in vivo translational models